-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on Blueprint Medicines, Maintains $128 Price Target

Benzinga·04/16/2025 14:02:00
Listen to the news
Wedbush analyst David Nierengarten reiterates Blueprint Medicines (NASDAQ:BPMC) with a Outperform and maintains $128 price target.